title: Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  We previously reported that glycemic control deteriorated in patients receiving atorvastatin, which is useful for the treatment of hypercholesterolemia in patients with type 2 diabetes. Pitavastatin has a strong lipid-lowering effect, comparable to that of atorvastatin, but it is unknown whether pitavastatin has an adverse influence on glycemic control. The aim of this study was to examine. The effects of three different statins (pravastatin, atorvastatin, and pitavastatin) on blood glucose and HbA(1C) levels in diabetic patients.
  
  
  METHODS
  We retrospectively compared glycemic control between groups receiving atorvastatin (10 mg/day, group A, n=99), pravastatin (10 mg/day, group Pr, n=85), and pitavastatin (2 mg/day, group Pi, n=95) from the start of treatment until 3 months later. Patients were excluded if the dosage of their antidiabetic drugs was changed, if their drug therapy was altered within 3 months before starting statin therapy, or if events occurred that could affect glycemic control such as hospitalization.
  
  
  RESULTS
  The subjects available for analysis were 74 patients from group A, 71 patients from group Pr, and 74 patients from group Pi. Arbitrary blood glucose levels increased from 147+/-51 mg/dL (mean+/-SD) to 176+/-69 mg/dL in group A, but only changed minimally from 136+/-31 to 134+/-32 mg/dL in group Pr and from 155+/-53 to 154+/-51 mg/dL in group Pi. HbA(1C) increased from 7.0+/-1.1% to 7.4+/-1.2% in group A, while it was 6.9+/-0.9% versus 6.9+/-1.0% in group Pr, and 7.3+/-1.0% versus 7.2+/-1.0% in group Pi. There was no correlation between Delta LDL-C and Delta HbA(1C) (the change from baseline to 3 months) in any of the groups.
  
  
  CONCLUSIONS
  The glycemic parameters only increased significantly in group A, suggesting that pitava-statin and pravastatin did not have an adverse influence on glycemic control in type 2 diabetic patients.
authors.affiliation: Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama, Japan. yamakat@urahp.yokoyhama-cu.ac.jp
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yamakawa
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Takano
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Tanaka
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D000069059:Atorvastatin; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004341:Drug Evaluation; D018149:Glucose Intolerance / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017035:Pravastatin / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D011804:Quinolines / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D000069059:Atorvastatin; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin; D011758:Pyrroles; D011804:Quinolines; C108475:pitavastatin